trending Market Intelligence /marketintelligence/en/news-insights/trending/24wf-KVXg7eZP472tRK51A2 content esgSubNav
In This List

Gemphire Therapeutics stockholders approve all-stock merger with NeuroBo

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Gemphire Therapeutics stockholders approve all-stock merger with NeuroBo

Gemphire Therapeutics Inc. stockholders approved the company's merger with privately held NeuroBo Pharmaceuticals Inc. in an all-stock deal.

Livonia, Mich.-based Gemphire said its stockholders also approved a reverse stock split wherein one new share will be exchanged for every 15 to 25 existing shares of the company.

Under the agreement, NeuroBo and Gemphire shareholders will own about 95.94% and 4.06% of the combined company, respectively.

The combined company will be named NeuroBo Pharmaceuticals and trade on the Nasdaq Capital Market under the symbol NRBO, which was also approved by Gemphire shareholders.

The merger is expected to close in mid-December, Gemphire said in a Dec. 6 press release.

Boston-based NeuroBo Pharmaceuticals is focused on developing therapies for neurodegenerative diseases and Alzheimer's disease.